In this large real-world study 🧪 using electronic health records 📊, GLP-1RAs and SGLT2is—two diabetes drugs 💉—were associated with a lower risk of Alzheimer’s and related dementias 🧠 in people with type 2 diabetes 🍬.

Both showed protective effects 🛡️, with no significant difference between them, suggesting promise for drug repurposing ♻️ in brain health strategies.